On Jul. 14, 2020, Shanghai Fosun Pharmaceutical announced it had received the acceptance notice of clinical trial application for the licensed COVID-19 vaccine product candidate BNT162b1 The clinical trial application of the Vaccine was accepted by the National Medical Products Administration.